<DOC>
	<DOCNO>NCT02259114</DOCNO>
	<brief_summary>Open-label , phase I , non-randomized , multicentric study single-agent OTX105/MK-8628 administer accord two distinct regimen participant select advanced tumor . The study perform two part . Dose Escalation Part : This step design determine maximum tolerate dose ( MTD ) two regimen , evaluate parallel . Participants receive oral OTX105/MK-8628 accord : Continuous Dosing Regimen : continuous , daily 21 consecutive day ( 21-day cycle ) . OR Days 1-7 Dosing Regimen : daily Days 1 7 , repeat every 3 week ( 21-day cycle ; 1 week ON/2 week OFF ) . Participants sequentially assign Continuous Dosing Regimen Days 1-7 Dosing Regimen accord next available place receive OTX105/MK-8628 escalate dos level ( DL ) . Cohorts 3 participant treat , additional 3 participant treat first indication dose-limiting toxicity ( DLT ) . MTD assessment base tolerability observe first 21 day treatment . Expansion Part : The efficacy OTX105/MK-8628 five indication ( i.e. , Bromodomain-Nuclear Protein Testis [ BRD-NUT ] midline carcinoma , triple negative breast cancer [ TNBC ] , non-small cell lung cancer [ NSCLC ] harbor rearrangement Anaplastic Lymphoma Kinase [ ALK ] gene/fusion protein Kirsten Ras [ KRAS ] mutation , castrate-resistant prostate cancer , pancreatic ductal carcinoma ) assess term response ( Response Evaluation Criteria Solid Tumors v1.1 [ RECIST v1.1 ] Prostate Cancer Clinical Trials Working Group 2 [ PCWG2 ] ) use select regimen .</brief_summary>
	<brief_title>A Dose-Finding Study OTX105/MK-8628 , Small Molecule Inhibitor Bromodomain Extra-Terminal ( BET ) Proteins , Adults With Selected Advanced Solid Tumors ( MK-8628-003 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>1 . Signed informed consent obtain prior initiation studyspecific procedures treatment ; 2 . Histologically cytologically confirm diagnosis one follow advanced metastatic solid tumor standard therapy either exist proven ineffective , intolerable inacceptable patient : NUT midline carcinoma ( ectopic expression NUT protein determine immunohistochemistry ( IHC ) and/or detection BRDNUT gene translocation determine fluorescence In situ hybridization [ FISH ] ) ; Triple negative breast cancer define accord American Society Clinical Oncology ( ASCO ) recommendation ( Hammond et al. , 2010 ; Wolff et al. , 2007 ) ; Nonsmall cell lung cancer harbor rearrange ALK gene/fusion protein ( FISH IHC ) KRAS mutation ( defined molecular analysis ) ; Castrateresistant prostate cancer ( CRPC ) ; Pancreatic ductal adenocarcinoma ; 3 . At least one measurable lesion per RECIST version 1.1. , except CRPC participant may enrol objective evidence disease per PCWG2 criterion ; 4 . Age ≥18 year time informed consent ; 5 . Life expectancy ≥3 month ; 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤1 ; 7 . Adequate bone marrow reserve , renal liver function : Absolute neutrophil count ≥1.5 x10^9/L , Platelet count ≥150 x10^9/L , Hemoglobin ≥9 g/dL , Creatinine clearance ≥30 mL/min calculate accord Cockroft Gault formula Modification Diet Renal Disease ( MDRD ) formula participant age &gt; 65 year , Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤3 x upper limit normal ( ULN ) total bilirubin ≤1.25 x ULN ( case liver involvement , ALT/AST ≤5 x ULN total bilirubin ≤2 x ULN allow ) , Serum albumin ≥2.8 g/dL , International Normalized Ratio ( INR ) ≤1.5 x ULN INR &lt; 3 participant treat antivitamin K ; 8 . An interval ≥3 week since chemotherapy ( ≥6 week nitrosoureas mitomycin C ) , immunotherapy , hormone therapy anticancer therapy surgical intervention resection , ≥3 halflives monoclonal antibody , ≥5 halflives noncytotoxic agent ( whichever longer ) ; 9 . CRPC participant must maintain ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue , antagonist orchiectomy provide serum testosterone &lt; 50 ng/dL ( &lt; 1.7 nmol/L ) ; 10 . Participants receive bisphosphonate denosumab therapy must stable dos least 4 week initiate study treatment . 1 . Inability swallow oral medication presence gastrointestinal disorder ( e.g . malabsorption ) deem jeopardize intestinal absorption OTX015/MK8628 ; 2 . Persistent grade &gt; 1 clinically significant toxicity relate prior antineoplastic therapy ( except alopecia ) ; stable sensory neuropathy ≤ grade 2 National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) v.4.0 accept . 3 . Known primary central nervous system ( CNS ) malignancy CNS involvement ; 4 . History prior concomitant malignancy ( excise nonmelanoma skin cancer cure situ cervical carcinoma ) within 3 year study entry ; 5 . Other serious illness medical condition , active infection , unresolved bowel obstruction , psychiatric disorder ; 6 . Known human immunodeficiency virus ( HIV ) positivity ; 7 . Participation another clinical trial treatment investigational drug within 30 day prior study entry ; 8 . Other concomitant anticancer treatment ; 9 . Concomitant therapy strong CYP3A4 interfering drug ; 10 . Current use anticoagulant ( e.g . warfarin , heparin ) therapeutic level within 7 day prior first dose OTX015/MK8628 . Lowdose ( prophylactic ) low molecular weight heparin ( LMWH ) permit ; 11 . Pregnant breastfeeding participant , men woman childbearing potential use effective contraception study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>